TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of ICU transfer or disease progression to severe or critical illness
Endpoint domain: Mortality/survival
Primary endpoint: Changes in immune cellular response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bayley II test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of NPM1 MRD negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation coefficient between LHPR and vein's surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to Medication Assisted Treatment (MAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug Use (Urine Drug Screens)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants achieving a complete remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients with fever
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of increase in tongue strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in score on Functional Oral Intake Scale (FOIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary BC Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area-under-curve (AUC) for SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean area-under-curve (AUC) for FiO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cognitive Mistakes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: rate of acute renal failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 24-hour Vancomycin Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in demoralization
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ventilator free day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface before dry needling in right foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface after dry needling in right foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface before Laser non-emission in right foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface after Laser non-emission in right foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of IGD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in stool MDRO colony-forming unit (CFU) density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in proportion of MDRO colonized participants after last treatment cycle with the investigational product (IP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: AUDIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of children who attended more than 75% of program sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of children who completed more than 80% of assessment activities
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: change in UACR level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to resolution of RSV LRTD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Percent Change in Self-rated Inventory of Depressive Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total amount of hs-CRP in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival rate during the clinical trial
Endpoint domain: Mortality/survival
Primary endpoint: WHO quality of life Bref
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Fear of Motion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nature and frequency of Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Nature and frequency of Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-limiting Toxicity (TLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Burden rate
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change of hepatic steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Score change of edematous fibrosclerotic panniculopathy (EFP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Bifidobacterium counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: macrophage activation in sarcoidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: monocyte activation in sarcoidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Monohydroxybutyl mercapturic acid (MHBMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Carboxyhemoglobin (COHb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Arm Circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum flow rate (MFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Post-voiding residual volume (PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary function (UF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Continence recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Dose of unsupervised therapy - Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose of unsupervised therapy - Repetitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose of unsupervised therapy - Percentual change in therapy time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline to Week 17 in mHTT Protein in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with treatment-emergent Adverse Events of Special Interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Eligible Participants Who Are Successfully Recruited and Attend at Least One Group Session
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Engagement as Measured by Number of Participants Who Attended More Than One Session
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Engagement as Measured by Number of Participants Who Completed PSA, IPC-18, MSSS, and CSQ-9 at All Time Points
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in 25(OH)vitamin D3 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: frequency of diarrheal episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Functional disability caused by low back pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Worst Itch-Numeric Rating Scale (WI-NRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the slope of SARS-COV 2 viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of free days from respiratory support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in 4-Meter Gait Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of sRPL patients with microchimeric male cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of sRPL patients with microchimeric cell originating from older brother
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of sRPL patients with microchimeric cell originating from the patient's son
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of sRPL patients with microchimeric cell originating from the patient's daughter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of sRPL patients with microchimeric cell originating from unknown person
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentrations of casirivimab+imdevimab in serum over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with treatment-emergent serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with infusion-related reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with hypersensitivity reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants who receive genetic testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: days alive out of hospital
Endpoint domain: Mortality/survival
Primary endpoint: change of health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Diagnostic precision of EOPE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAP1 homocysteinylation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of dogs detecting COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of dogs detecting COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity precision of dogs to detect COVID-19 in humans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement metrics
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Area under curve for dopaminergic agonist treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast milk excretion of Human Milk oligosaccharide content (HMO) content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Infant Gastrointestinal Symptom Questionnaire (IGSQ) index score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total recovery of radioactivity in urine and feces as percentage of total radioactive dose administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of intravenous radiolabeled PF-07304814 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of intravenous radiolabeled PF-07304814 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International RLS Rating Scale (IRLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and Percentage of Patients Converting to General Anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Stress level assessed by the salivary cortisol test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Stress level assessed by the perceived stress scale (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fugel Meyer assessment scale for upper limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the DI Magnet System
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of a major haemodynamic disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response rate (complete remission plus complete remission with incomplete blood count recovery)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of patients able to proceed to stem cell transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Caregiver-child bond
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accuracy of Pulse Oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tooth functional retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good neurologic outcome
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: venous thromboembolism occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Cancer Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Survival rate of Class II restorations
Endpoint domain: Mortality/survival
Primary endpoint: Mandibular Preservation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) After a Single Dose of Cefiderocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve Extrapolated From Time 0 to Infinity (AUC0-inf) After Single Dose of Cefiderocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Elimination Half-Life (t1/2) After a Single Dose of Cefiderocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of grade 3 and grade 4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Days with a Temperature Reading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients with navigation nurse intervention files received
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diastasis healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Regional brain distribution of radiolabeled white blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Feasibility of administering dinutuximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average dinutuximab infusion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year recurrence free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Recurrent fever episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Global Deterioration Scale-Functional Assessment Staging (GDS-FAST)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: percent of leukocytes expressing Sialyl-Lewis X antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quadriceps measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Monthly volume of prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Instrumental vaginal delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Agreement on QRS width
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Agreement on PR interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Agreement on AT interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mechanical properties of breast implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: urethral sphincter pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: variation of carotid intima media thickness (CIMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Autoantibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarker testing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Efficacy of peri capsular nerve group block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline leucocytes count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Baseline tumor-infiltrating lymphocytes count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of [18F]-FAPI-74 uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects recruited
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of subjects who complete the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of dosages of drug/placebo that are taken by participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diagnostic Yield of wearable electrocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in understanding how to use a power mobility device
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in power mobility skill performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in electroencephalography (EEG) measures between arousal and anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of mRS score 0-2 at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of dysplastic or SSA lesions detected per colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pediatric Rehabilitation Intervention Measure of Engagement - Parent version (PRIME-P)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in post-stroke cognitive impairment and dementia diagnosis status
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Humoral Immune Response (Neutralizing antibody)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Wrinkle change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in skin firmness and elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Healthcare provider recommendation for low dose aspirin use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Difference in skin conductance response (SCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Difference in frontomedial theta power (EEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hip disability & Osteoarthritis Outcome Score (HOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Osteoarthritis severity assessed with radiographic scoring system (Tönnis classification)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment-emergent side effects measured with the NSEC
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of relapse free survival (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of non-relapse mortality (NRM)
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of overall mortality
Endpoint domain: Mortality/survival
Primary endpoint: Myopic shift of spherical equivalent refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spot to background ratio for tumor positive and tumor negative margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Vital Signs-blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Number of Missed Bolus Doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent compliance for total at-home sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of adverse maternal outcome related to hypertension
Endpoint domain: Adverse events/effects
Primary endpoint: C. difficile acquisition rates
Endpoint domain: Adverse events/effects
Primary endpoint: Subject's Occurrence Rate of Study Valve Related Death
Endpoint domain: Mortality/survival
Primary endpoint: Subject's Occurrence Rate of Structural Valve Deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Subject's Occurrence Rate of Major Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Relative bioavailability of Micronized dispersible ferric pyrophosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Minimal residual disease (MRD) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes